We're crowdfunding! Own a part of our business. Capital at Risk.
View our pitch
Crowdcube

StablevaX™ technology underpins the development of a new generation
of fridge-free vaccines & pharmaceuticals.

Leading this portfolio is SPVX02 —the first-ever thermostable tetanus
and diphtheria vaccine to advance into clinical evaluation.

Our streamlined regulatory pathway cuts timelines by relying on one pivotal trial or bioequivalence study—accelerating access to fridge-free vaccines and lifesaving pharmaceuticals.

Focussed on Innovation

Our R&D portfolio focuses on innovation in improving existing and new vaccine and pharmaceutical products, to ensure continued expansion and growth. With our network of key partners, we continue to build strong relationships with pharmaceutical manufacturers and NGOs to advance a pipeline of reformulated, fridge-free products to enable everyone, everywhere access to lifesaving medicines.

Our Pipeline and Partnerships

Our Partners

MENU